Real-world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: the COALA project
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: -mutated metastatic colorectal cancer (mCRC) is a biologically distinct and clinically aggressive subtype associated with poor outcomes. Real-world data on this population remains limited, particularly within the Australian health care setting. Patients and methods: The COALA study is a national, prospective registry-based observational analysis of patients with mCRC across 21 Australian institutions. Data were extracted from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) and TRACC-Select registries and included demographics, molecular profiles, treatment patterns and overall survival (OS). Uptake and impact of encorafenib plus cetuximab (EC), since being available in Australia from May 2019, were examined. Results: patients receiving 2L therapy, EC use versus chemotherapy was associated with a trend for improved OS (HR 0.70, median 8.6 versus 6.8 months). Conclusions: -mutated mCRC. These findings underscore the importance of early and effective therapeutic strategies, and identify a novel, disproportionately affected very-young subgroup requiring targeted research and clinical focus.
Institutions: Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre, Eastern Health, Monash University, Cabrini Hospital, Royal Brisbane and Women's Hospital, Royal Hobart Hospital, Northern Health, Camden and Campbelltown Hospitals, Barwon Health, Gold Coast Hospital, Western Health, Grampians Health, Cairns Hospital, Edith Cowan University, Fiona Stanley Hospital, Lake Macquarie Private Hospital, Goulburn Valley Health, The University of Melbourne, Latrobe Regional Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
Funder: Fondation Pierre Fabre
OpenAlex ID: W4413923564